Friday - December 27, 2024

Methods to Treat Mucopolysaccharidosis Type II or Deficiency in Iduronate-2-Sulfatase Using a Recombinant Adeno-Associated Virus (AAV) Vector Encoding Iduronate-2-Sulfatase

2024-10-22

ALEXANDRIA, Virginia, Oct. 22 -- REGENXBIO INC., Rockville, Maryland has been assigned a patent (No. US 12121567 B2, initially filed Sept. 27, 2017) developed by five inventors R. Scott McIvor, St. Louis Park, Minnesota; Lalitha R. Belur, St. Paul, Minnesota; Walter Low, Shorewood, Minnesota; Carolyn Fairbanks, St. Paul, Minnesota; and Karen Kozarsky, Bala Cynwyd, Pennsylvania, for "Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-a . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Methods to Treat Mucopolysaccharidosis Type II or Deficiency in Iduronate-2-Sulfatase Using a Recombinant Adeno-Associated Virus (AAV) Vector Encoding Iduronate-2-Sulfatase

Information Request Form

Copyright Targeted News Service 2024